In this article
FDA Approval of Belzutifan for Advanced Renal Cell Carcinoma
The Food and Drug Administration granted approval for belzutifan (Welireg, Merck & Co., Inc.) on December 14, 2023, for patients with advanced renal cell carcinoma (RCC) who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
LITESPARK-005 Clinical Trial and Efficacy Comparison
The effectiveness was assessed in LITESPARK-005 (NCT04195750), a study where 746 patients with unresectable locally advanced or metastatic clear cell RCC were randomly assigned to different treatments after progressing following a PD-1 or PD-L1 checkpoint inhibitor and a VEGF-TKI. Participants were randomly assigned in a 1:1 ratio to receive either 120 mg of belzutifan or 10 mg of everolimus once a day. Randomization was categorized based on the International Metastatic RCC Database Consortium risk group and the quantity of preceding VEGF-TKIs.
Progression-Free Survival and Patient Tolerance
The primary effectiveness measures were progression-free survival (PFS) evaluated by blinded independent central review and overall survival (OS).
Belzutifan showed a statistically significant improvement in progression-free survival (PFS) compared to everolimus, with a hazard ratio of 0.75 (95% CI: 0.63, 0.90) and a one-sided p-value of 0.0008. The Kaplan-Meier curves showed non-proportional risks with comparable median progression-free survival estimates of 5.6 months (95% CI: 3.9, 7.0) in the belzutifan group and 5.6 months (95% CI: 4.8, 5.8) in the everolimus group. Although the OS data were incomplete at the current study, with 59% of fatalities reported, no negative trend was detected. An examination of patient-reported symptoms and functional outcomes indicated that belzutifan was better tolerated than everolimus.
Common Adverse Effects and Laboratory Abnormalities
The predominant adverse effects (≥25% occurrence) observed in patients treated with belzutifan included reduced hemoglobin levels, fatigue, musculoskeletal pain, elevated creatinine levels, decreased lymphocyte count, elevated alanine aminotransferase levels, reduced sodium levels, elevated potassium levels, and increased aspartate aminotransferase levels.
Recommended Dosage and Administration
The suggested belzutifan dosage is 120 mg taken orally once a day until disease progression or intolerable toxicity.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.